在心力衰竭和减少喷射分数的老年患者中使用 vericiguat 的实际考虑
Francesco Castelletti1, Elena Bianco1, Giulia Fabro1
1Medical Center, Department of Internal Medicine, Ospedale di Circolo & Fondazione Macchi, ASST Sette Laghi, Varese, Italy.
European journal of clinical investigation
|February 19, 2026
概括
韦里西瓜特是建议治疗心力衰竭 (WHF) 恶化的患者,减少喷射率 (HFrEF). 其有利的副作用特征使其适合于老年,脆弱的个体,改善服药性并减少停药.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 恶化的心力衰竭 (WHF) 显著影响预后,需要改进的管理策略,特别是心力衰竭与减少喷射率 (HFrEF).
- 目前的指南导向医疗治疗 (GDMT) 在老年,脆弱的HFrEF患者中可能难以实施,原因是并发症和潜在的副作用.
研究的目的:
- 评估 vericiguat作为一种治疗选择,HFrEF患者经历了恶化的心力衰竭.
- 要突出 vericiguat 在这个患者群体的优势,包括易于管理和有利的安全性.
主要方法:
- 维多利亚试验证明了 vericiguat在减少HFrEF患者的HF住院或心血管死亡方面的有效性.
- 观察性研究证实了这些积极的发现.
- 在VICTOR试验中,还评估了HFrEF患者没有最近的WHF的 vericiguat.
主要成果:
- 根据心力衰竭指南,推使用Vericiguat与IIb表示.
- 维里西瓜特提供优势,如每天服用一次,耐受性好,副作用有限,如低血压.
- 它不需要例行实验室检测或治疗药物监测,提高患者的遵守性.
结论:
- 在有WHF病史的HFrEF患者中,应考虑早期使用Vericiguat,这可能是GDMT的第五支柱.
- 虽然VICTOR试验没有显示HFrEF患者最近没有WHF的复合结果减少,但它确实证明了心血管和全因死亡率的好处.
更多相关视频
04:48Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
Published on: November 28, 2018
7.0K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.0K
相关概念视频
01:22Heart Failure Drugs: Diuretics
1.8K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.8K
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:15Drug Dosing: Geriatric Patients
400
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
400
01:30Heart Failure IV: Classification and Diagnostic Evaluation
1.2K
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1.2K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635